The Blood–Brain Barrier and Epilepsy

  title={The Blood–Brain Barrier and Epilepsy},
  author={Emily R. Oby and Damir Janigro},
  • E. Oby, D. Janigro
  • Published 1 November 2006
  • Biology, Psychology, Medicine
  • Epilepsia
Summary:  During the past several years, there has been increasing interest in the role of the blood–brain barrier (BBB) in epilepsy. Advances in neuroradiology have enhanced our ability to image and study the human cerebrovasculature, and further developments in the research of metabolic deficiencies linked to seizure disorders (e.g., GLUT1 deficiency), neuroinflammation, and multiple drug resistance to antiepileptic drugs (AEDs) have amplified the significance of the BBB's relationship to… 
The Blood-Brain Barrier in Epilepsy
Three critical components of barrier function 1) tight junctions, 2) metabolising enzymes and 3) transporter proteins are introduced and it is described how they are changed in epilepsy and affected by epilepsy treatment.
Blood–brain barrier dysfunction and epilepsy: Pathophysiologic role and therapeutic approaches
A BBB‐centric view of seizure disorders is offered, linking several aspects of seizures and epilepsy physiopathology to BBB dysfunction, and the therapeutic, antiseizure effect of drugs that promote BBB repair is reviewed.
The blood–brain barrier in health and disease
This review discusses the cellular and molecular composition of the blood–brain barrier and how the development and function of the BBB is regulated by interactions with the CNS microenvironment.
Blood-Brain Barrier Dysfunction in Epileptogenesis of the Temporal Lobe
New evidence is provided to support the hypothesis that BBB breakdown and specifically exposure of temporal lobe structures to the most common serum protein, albumin, is sufficient to induce epileptogenesis.
Atorvastatin treatment during epileptogenesis in a rat model for temporal lobe epilepsy
This work aimed to restore the integrity of the blood–brain barrier in epileptic rats using atorvastatin to reduce brain inflammation, thereby delaying or preventing the development of epilepsy.


Epilepsy and the blood-brain barrier.
Indirect evidence is available to suggest that during seizures, BBB transport may indeed be the rate-limiting step, and glucose availability to the seizing brain may be restricted to such a degree that brain glucose utilization rates are no longer independent of plasma glucose levels.
Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory Epilepsy
It was suggested that altered drug permeability across the blood–brain barrier (BBB) may be involved in pharmacoresistance to antiepileptic drugs (AEDs) and multiple drug resistance (MDR) gene expression in endothelial cells isolated from temporal lobe blood vessels of patients with refractory epilepsy was measured.
Drug resistance in epilepsy: the role of the blood-brain barrier.
Evidence that under pathological conditions, 'second line defence' mechanisms in perivascular glia may be up-regulated, including expression of Pgp and other drug efflux transporters complicates interpretation of drug resistance in epilepsy, and therapeutic strategies is found.
The blood–brain barrier: an overview Structure, regulation, and clinical implications
Reading and writing the blood-brain barrier: relevance to therapeutics.
These techniques for both "reading" and "writing" the BBB will help new and old medications to reach their pharmacological targets in the CNS.
Lasting Blood-Brain Barrier Disruption Induces Epileptic Focus in the Rat Somatosensory Cortex
This study established a model for focal disruption of the blood-brain barrier in the rat cortex by direct application of bile salts and found that a focus of epileptiform discharges developed within 4-7 d after treatment and could be recorded up to 49 d postoperatively in >60% of slices from treated animals but only rarely in sham-operated controls.
The blood-brain barrier as a target for pharmacological modulation.
The endogenous iron/transferrin transport system has been used extensively preclinically to deliver intravenously administered nerve growth factor to the brain and serves as the major focus for this discussion.
Molecular and cellular mechanisms of pharmacoresistance in epilepsy.
An emerging understanding of the molecular underpinnings of both transporter- and target-mediated mechanisms of pharmacoresistance in human and experimental epilepsy is likely to provide important impetus for the development of new pharmacological treatment strategies.
Drug delivery and in vitro models of the blood-brain barrier.
A great effort has been made to develop new in vitro models able to reproduce the physiological, anatomical and functional characteristics of the blood-brain barrier allowing for a better prediction of drug penetration across the BBB, and enabling the design of new pharmaceutical strategies to bypass the shielding of brain parenchyma.